AB Genomics – About the Company

logo-ab-genomics
AbGenomics (private) is a biopharmaceutical company developing antibody therapeutics for inflammatory diseases and cancer. The Company’s lead candidate is AbGn-168H (neihulizumab), a targeted therapy for the treatment of acute graft-vs-host disease (aGvHD). AbGn-168H is currently being evaluated in a Phase Ib trial in steroid refractory aGvHD, with results expected in the second half of 2016. Results from a proof-of-concept Phase II trial in psoriatic arthritis (PsA) demonstrated that 40% of subjects treated with AbGn-168H achieved a 20% reduction in symptoms at week 12. The Company’s preclinical oncology product candidates are next generation antibody drug conjugates (ADC) for solid tumors.